HEMOFIL® M and RECOMBINATE® Discontinuation Timelines

Two therapies used to treat hemophilia A, including the first ever recombinant therapy for hemophilia, will eventually be discontinued. Manufacturer Takeda recently shared a timeline on how long these treatments will remain available for patients currently using them. In a letter to patients, the company stated that Hemofil M will be supplied through September 2026. Recombinate will also remain available through September 2026, with select vial sizes (250 IU and 2000 IU) expected to continue through March 2027. The decision to discontinue both therapies is not related to safety or efficacy concerns. Patients who currently rely on these treatments should speak with their healthcare provider or hemophilia treatment center to discuss alternative therapy options that best meet their individual needs. Read more here.

LA Kelley Communications, Inc., Communique, April 2026